Recce Limited is seeking to raise up to $5 million through an initial public offering of 25 million shares priced at $0.20 to further development of its antibiotics that target otherwise antibiotic-resistant bacteria.
The company’s synthetic RECCE polymer-antibiotics are synthesised by a substantially patented and potentially highly economic manufacturing process.
Early tests conducted to date indicate that its antibiotics always kill superbugs without creating bacterial resistance.
Proceeds from the IPO will be used over two years to undertake both the development of a production ‘model’, and the pre-clinical regulatory requirements of its antibiotics designed for human use.
The company aims to manufacture active pharmaceutical ingredients of RECCE antibiotics for its own use or possible sale to a leading global pharmaceutical company, for inclusion in their end-product medicine.
It seeks to trade as RCE on the Australian Securities Exchange.
News: Recce Limited seeks to raise up to $5M through IPO
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
-0.005(1.28%) |
Mkt cap ! $111.3M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 38.5¢ | 37.0¢ | $21.54K | 57.86K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3248 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 49884 | 1 |
View Market Depth
| Last trade - 14.27pm 30/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |